论文部分内容阅读
目的探讨新辅助放疗治疗中晚期宫颈癌的疗效及临床分析。方法 2007年7月至2009年7月期间,我院诊治的68例中晚期宫颈癌患者,随机将其分为对照组(常规放疗)和观察组(新辅助放疗),每组各34例,对两组患者的3年生存率、毒副反应,进行观察和比较。结果与对照组相比,观察组放射性肠炎、放射性膀胱炎等毒副反应的发生率明显降低,而3年生存率明显升高,P<0.05,差异有统计学意义。结论新辅助放疗减少了放疗的毒副反应,提高了患者的生存率,还为复发病灶的再次放疗,提供了剂量空间,值得临床推广。
Objective To investigate the efficacy and clinical analysis of neoadjuvant radiotherapy for advanced cervical cancer. Methods From July 2007 to July 2009, 68 cases of advanced cervical cancer treated in our hospital were randomly divided into control group (conventional radiotherapy) and observation group (neoadjuvant radiotherapy), 34 cases in each group, The 3-year survival rate and toxicity of the two groups of patients were observed and compared. Results Compared with the control group, the incidence of radioactive enteritis and radioactive cystitis in the observation group was significantly lower than that in the control group, but the 3-year survival rate was significantly increased (P <0.05). The difference was statistically significant. Conclusions Neo-adjuvant radiotherapy can reduce the side effects of radiotherapy and improve the survival rate of patients. It also provides dose space for re-radiotherapy of recurrent lesions, which is worthy of clinical promotion.